Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers

Cytotherapy

Volumn 15, Issue 2, 2013, Pages 231-241.e1

  Kim, Eun Kyung ^a,c   Ahn, Yong Oon ^a,c   Kim, Saerom ^a,c   Kim, Tae Min ^a,b,c   Keam, Bhumsuk ^a,b,c   Heo, Dae Seog ^a,b,c  

^a Cancer Research Institute   (South Korea)

^b Department of Internal Medicine ^*  (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Advanced cancer; Autologous cell therapy; Ex vivo expansion; Feeder cells; NK cells

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER PATIENT; CELL EXPANSION; CELL GROWTH; CELL ISOLATION; CHONDROSARCOMA; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DERMATITIS HERPETIFORMIS; EX VIVO STUDY; FEEDER CELL; FEMALE; FOLLICULAR DENDRITIC CELL SARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MANTLE CELL LYMPHOMA; MONONUCLEAR CELL; NASOPHARYNX CANCER; NATURAL KILLER CELL; NK T CELL LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84875480259     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2012.10.019     Document Type: Article

References (31)

1. Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity. 1995;3:459-73.
2. Caligiuri MA. Human natural killer cells. Blood. 2008;112: 461-9.
3. Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol. 2001;29:1157-68.
4. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984; 160:1147-69.
5. London L, Perussia B, Trinchieri G. Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. J Immunol. 1986; 137:3845-54.
6. Lanier LL, Buck DW, Rhodes L, Ding A, Evans E, Barney C, et al. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J Exp Med. 1988;167:1572-85.
7. Robertson MJ, Manley TJ, Donahue C, Levine H, Ritz J. Costimulatory signals are required for optimal proliferation of human natural killer cells. J Immunol. 1993;150:1705-14.
8. Srivastava S, Lundqvist A, Childs RW. Natural killer cell immunotherapy for cancer: a newhope.Cytotherapy. 2008;10:775-83.
9. Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood. 1992;80:2221-9.
10. Rabinowich H, Sedlmayr P, Herberman RB, Whiteside TL. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells. Cell Immunol. 1991;135:454-70.
11. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004;104:170-7.
12. Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul. 1987;6:171-88.
13. Ohno T, Harada H, Saijo K, Watanabe S, Tsuboi K, Nose T, et al. Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT. Jpn J Cancer Res. 2002;93:313-9.
14. LuhmJ, BrandJM,Koritke P,HoppnerM,KirchnerH,FrohnC. Large-scale generation of natural killer lymphocytes for clinical application. J Hematother Stem Cell Res. 2002;11:651-7.
15. Condiotti R, Zakai YB, Barak V, Nagler A. Ex vivo expansion of CD56 cytotoxic cells from human umbilical cord blood. Exp Hematol. 2001;29:104-13.
16. Boissel L, Tuncer HH, Betancur M, Wolfberg A, Klingemann H. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant. 2008;14:1031-8.
17. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.Blood. 2005;106:376-83.
18. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69:4010-7.
19. Konjevic G, Mirjacic Martinovic K, Jurisic V, Babovic N, Spuzic I. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16 NK cells. Biomarkers. 2009;14:258-70.
20. Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother. 2010;59:73-9.
21. Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, et al. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol. 2005;23:7105-13.
22. Carlsten M, Bjorkstrom NK, Norell H, Bryceson Y, van Hall T, Baumann BC, et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007;67:1317-25.
23. Lotzova E, Savary CA, Freedman R, Bowen JM. Natural immunity against ovarian tumors. Comp Immunol Microbiol Infect Dis. 1986;9:269-75.
24. Phillips JH, Lanier LL. Dissection of the lymphokineactivated killer phenomenon: relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986;164:814-25.
25. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051-7.
26. Cooper MA, FehnigerTA, CaligiuriMA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633-40.
27. Wilk E, Kalippke K, Buyny S, Schmidt RE, Jacobs R. New aspects of NK cell subset identification and inference of NK cells' regulatory capacity by assessing functional and genomic profiles. Immunobiology. 2008;213:271-83.
28. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458-65.
29. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med. 1998;187:2065-72.
30. Biassoni R, Bottino C, Cantoni C, Moretta A. Human natural killer receptors and their ligands. Curr Protoc Immunol. 2002. Chapter 14:Unit 14.10.
31. Sutlu T, Stellan B, Gilljam M, Quezada HC, Nahi H, Gahrton G, et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy. 2010;12:1044-55.